My Cart

Human DR3 (TL1A receptor) (Luc) Jurkat Reporter Cell

Customer Reviews
Cat. No. / Size
Price
Qty
SCJUR-STF178-2Vials (1Vial X 2)
$14220.00
ETA of in-stock products:2 business days
Sub-Total$ 0

Product Details

    1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
    2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
    3. Comprehensive application data to support assay development and validation
    4. Full tracible record, stringent quality control and validated cell passage stability
    5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
    6. Global commercial license assistance whenever regulatory filing is required
  • Description

    The Human DR3 (TL1A receptor) (Luc) Jurkat Reporter Cell was engineered to not only express the NF-κB signaling response element, but also express the receptor human DR3 (TL1A receptor) (Uniprot: Q93038-1). When stimulated with human TL1A protein, the TL1A/DR3 interaction drives NF-κB-mediated luminescence. Inhibition of TL1A binding to DR3 by either anti-TL1A or anti-DR3 antibodies results in a decrease in luminescence.

  • Application

    • Screen for neutralizing antibodies blocking the stimulation of human TL1A protein.

    DR3 Assay Principles

  • Growth Properties

    Suspension

  • Selection Marker

    Hygromycin B (20 μg/mL)

  • Complete Growth Medium

    RPMI-1640 + 10% FBS

  • Freeze Medium

    Serum-free cell cryopreservation medium

  • Quantity

    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

  • Storage

    Frozen in liquid nitrogen.

  • Mycoplasma Testing

    Negative

  • Sterility Testing

    Negative

  • Instructions for Use

    See data sheet for detailed culturing and assay protocol.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • Application

     DR3 APPLICATION

    Inhibition of human TL1A protein-induced reporter activity.
    This reporter cell was incubated with serial dilutions of antibodies in the presence of human TL1A protein (Cat. No. TLA-H5243) with a final concentration of 0.02 μg/mL. The EC50 of anti-human TL1A neutralizing antibody is approximately 0.018 μg/mL.

    Protocol
  • Signaling Bioassay

     DR3 SIGNALING

    Response to human TL1A protein (RLU).
    This reporter cell was incubated with serial dilutions of human TL1A protein (Cat. No. TLA-H5243). The EC50 was approximately 0.014 μg/mL.

    Protocol
  •  DR3 SIGNALING

    Response to human TL1A protein (FOLD).
    This reporter cell was incubated with serial dilutions of human TL1A protein (Cat. No. TLA-H5243). The max induction fold was approximately 54.12.

    Protocol
  • Passage Stability

     DR3 PASSAGE

    Passage stability analysis by Signaling Bioassay.
    The continuously growing Human DR3 (TL1A receptor) (Luc) Jurkat Reporter Cell was stimulated with serial dilutions of human TL1A protein (Cat. No. TLA-H5243). Human TL1A protein stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 10-23.

    Protocol
*Please contact us if you are interested in related cell pool service.

Customer Reviews
Writing Reviews

Important Statement

  • Limited Use&License Disclosure

    BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.

    1. If the researcher is not willing to accept the terms of limited use of this cell line product, and the product is unused, ACRO will accept return of the unused product.
    2. Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for profit or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research.
    3. This cell line is neither intended for any animal or human therapeutic purposes nor for any direct human in vivo use. You have no right to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
    4. ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
    5. ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
    6. Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order@acrobiosystems.com for further details.

Recent Advances

 
Contact Us
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Important Statement
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland